Accelerating the speed of innovative anti-tumor drugs to first-in-human trials incorporating key de-risk strategies
Description
Pharmaceutical companies have recently focused on accelerating the timeline for initiating first-in-human (FIH) trials to allow quick assessment of biologic drugs. For example, a stable cell pool can be used to produce materials for the toxicology
